{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:23:35Z","timestamp":1777998215077,"version":"3.51.4"},"reference-count":7,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T00:00:00Z","timestamp":1170720000000},"content-version":"vor","delay-in-days":281,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skinmed"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:p> <jats:italic>\n            <jats:bold>Background and Objective<\/jats:bold>. The therapeutic efficacy of the tretinoin products Tretin\u2010X (Triax Pharmaceuticals, Cranford, NJ) and Retin\u2010A (Johnson &amp; Johnson, New Brunswick, NJ) in the treatment of acne vulgaris was compared in four bioequivalence studies.<\/jats:italic> <\/jats:p><jats:p> <jats:italic>\n            <jats:bold>Methods<\/jats:bold>. Four double\u2010blind, three\u2010treatment, parallel\u2010group studies randomly assigned 1642 adolescents and adults, 12\u201340 years of age, with mild\u2010to\u2010severe acne vulgaris to receive topical tretinoin therapy with Tretin\u2010X, Retin\u2010A, or placebo (drug vehicle) as 0.1% cream (study 1), 0.025% cream (study 2), 0.025% gel (study 3), and 0.01% gel (study 4) once daily for 84 days. The primary efficacy measures were overall acne severity and the number of inflammatory lesions. The secondary efficacy measure was the total number of lesions.<\/jats:italic> <\/jats:p><jats:p> <jats:italic>\n            <jats:bold>Results<\/jats:bold>. In each trial, Tretin\u2010X and Retin\u2010A were clinically equivalent according to all primary and secondary end points at Weeks 2, 4, 8, and 12, a finding also demonstrated by the averaged scores from Weeks 2 through 12. Moreover, each active treatment was significantly more efficacious than placebo at the conclusion of the study (<\/jats:italic> p<jats:italic>\u22640.05). Both of the Tretin\u2010X and Retin\u2010A formulations compared in each study were well tolerated. The severity of erythema and peeling did not differ significantly among the three groups studied. Conclusions. The four bioequivalence studies demonstrated that Tretin\u2010X and Retin\u2010A tretinoin products behaved similarly in patients with mild\u2010to\u2010severe acne vulgaris and were thus clinically bioequivalent. Both treatments were well tolerated, and their associated adverse events were similar to those with placebo.<\/jats:italic><\/jats:p>","DOI":"10.1111\/j.1540-9740.2006.05606.x","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T00:53:03Z","timestamp":1170809583000},"page":"114-118","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Tretin\u2010X Compared With Retin\u2010A in Patients With Mild\u2010to\u2010Severe Acne Vulgaris"],"prefix":"10.1111","volume":"5","author":[{"given":"Webster","family":"Guy F.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,6]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1795","article-title":"Dermatological pharmacology","author":"Wyatt EL","year":"2001","journal-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7362.475"},{"key":"e_1_2_5_4_2","first-page":"5","article-title":"Current concepts in the treatment of acne: report from a clinical roundtable","volume":"72","author":"Berson DS","year":"2003","journal-title":"Cutis"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00929.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410033006"},{"key":"e_1_2_5_7_2","first-page":"167","article-title":"Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris","volume":"72","author":"Shalita AR","year":"2003","journal-title":"Cutis"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.009"}],"container-title":["SKINmed: Dermatology for the Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-9740.2006.05606.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-9740.2006.05606.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:00:13Z","timestamp":1696989613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-9740.2006.05606.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1540-9740.2006.05606.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-9740.2006.05606.x","archive":["Portico"],"relation":{},"ISSN":["1540-9740","1751-7125"],"issn-type":[{"value":"1540-9740","type":"print"},{"value":"1751-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}